Objectives: The aim of this study was to determine if spotty calcification decreases the response of plaque progression to statin therapy.
correlation exists between arterial calcification and plaque burden [2] .
CAC plays an active role in plaque development by its action on macrophage activation, which places patients at higher risk for acute coronary events due to the increment of inflammation [3, 4] . Previous studies detected arterial wall calcium deposits in vivo [5] , and small calcium deposits were more significantly observed in the culprit lesion segment in acute coronary syndrome (ACS) patients using intravascular ultrasound (IVUS) [6] . Kataoka et al. studied atheroma progression in patients with spotty calcification using IVUS and showed that despite the use of medical therapies, spotty calcification was associated with accelerated disease progression and constructive positive modeling [7] . The high resolution of optical coherence tomography (OCT) allows the direct visualization of the plaque microstructure contributing to plaque vulnerability [8, 9] . Recent OCT studies showed that lesions with spotty calcification had thinner fibrous cap thicknesses and demonstrated vulnerable plaque features [10] . In addition, spotty calcification is an independent predictor of plaque rupture in patients with ACS [11] . These findings implied that spotty calcification is a marker of plaque vulnerability in patients presenting with acute coronary syndrome.
Therefore, we sought to assess the relationship between spotty calcification and plaque progression at nonculprit lesions in response to statin therapy using OCT in patients with coronary artery disease.
| M A TE RI A L S A ND M E TH ODS

| Study population
The current study population was from a prospective, randomized trial, which was performed to evaluate the progression of lipid-rich plaques treated with intensive versus moderate statin therapy at baseline and 6 and 12 month follow-ups [12] [ClinicalTrial.gov registered number: NCT01023607]. A total of 120 consecutive patients who underwent successful percutaneous coronary intervention (PCI) were enrolled in the study from September 2009 to March 2013 at the 2nd Affiliated Hospital of Harbin Medical University. The study criteria were reported previously [12] .
All lipid-rich plaques were analyzed according to landmark at index and 6 and 12 month follow-ups. Fifty-one patients were excluded for the following reasons: (a) withdrawn (n 5 31), (b) poor imaging (n 5 13), and (c) image mismatch (n 5 7). Finally, in our analysis, ninetysix lipid-rich plaques from sixty-nine patients who underwent serial OCT images (baseline, 6 months and 12 months) were divided into three groups based upon the distribution of the calcium: spotty calcification, calcified, and noncalcified group shown in Figure 1 All patients provided written informed consent, and this trial was approved by the Ethics Committee of the 2nd Affiliated Hospital of Harbin Medical University (Harbin, China).
| OCT image acquisition and analysis
All OCT procedures were performed after an intra-coronary administration of 100-200 mg of nitroglycerin. OCT imaging was performed using a time-domain (M3 Cardiology Imaging System; LightLab Imaging, Westford, Massachusetts) or frequency domain OCT system (C7-XR OCT Intravascular Imaging System, St. Jude Medical, St. Paul, Minnesota). Offline software (Light Lab Imaging) was used for OCT image analysis at an independent core laboratory of the 2nd Affiliated Hospital of Harbin Medical University. OCT images were analyzed at 1-mm intervals. All baseline and follow-up OCT images were analyzed by two independent reviewers who were blinded to clinical information. OCT images were analyzed according to the criteria previously reported [13] . A third professional investigator intervened when there was any discordance between the observers, and consensus was obtained.
The target lesions were determined according to coronary angiography. The corresponding segments at 6-and 12-month follow-ups were identified on the basis of reliable anatomic marks, such as the side branches, calcifications, and stent edges. All the enrolled plaques should be at least 5 mm away from either the distal or proximal stent edge.
All OCT images were analyzed using the previously validated criteria for plaque characterization [13] [14] [15] . Lipid-rich plaques were defined as plaques with lipid contents >1008 and FCTs <120 lm on the OCT image according to a previous study's definition [12] . The characteristic of a lipid core was a diffusely bordered, signal-poor region [15] . FCT covering the lipid core was measured at its thinnest part three times, and the average value of the three measurements was used for subsequent analysis. At follow-up, FCT was measured at the same site that it was measured at baseline, according to a landmark, using the same methodology. The lipid arc was measured on the cross-section with largest lipid core. Calcification was defined as an area with low backscattering signal and a sharp border [15] . Spotty calcification was defined as the presence of lesions <4 mm in length and containing an arc of calcification <908 according to the definition of previous studies using gray-scale intravascular ultrasound [6, 7] . Thin-cap fibroatheroma (TCFA) was defined as a plaque with lipid content in 2 quadrants and the thinnest part of FCT 65 mm on a cross-sectional image [13] . 
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Macrophage infiltration was defined as signal-rich, distinct regions that exceeded the intensity of background speckle noise [16] . A microchannel was defined as signal-poor voids without a connection to the vessel lumen recognized on more than three consecutive cross-sectional OCT frames [8, 13] . Thrombus was defined as a floating or protruding mass into the lumen with a dimension 25 mm [17] . Cholesterol crystals were defined as linear and highly backscattering structures within the lipid-rich plaques [13] . Categorical data were expressed as absolute number and percentage and were compared using either a chi-square test or Fisher's exact test, depending on the data, while for the comparison of continuous results in three groups over the three time points, 1-way ANOVA with Bonferroni correction for post hoc comparisons was applied. Generalized estimating equations approaches were used to take into account the intraclass correlation due to the multiple plaques analyzed within a single patient's data. A value of P < .05 was considered statistically significant.
| RE S U L TS
| Baseline patient clinical characteristics
Baseline characteristics of patients are summarized in Table 1 . There was a significant difference in age (P 5 0.023) and the treatment of nitrates at discharge (P 5 0.011) between spotty calcification and noncalcified group. A history of hypertension was more common in patients with spotty calcification compared with noncalcified patients (P 5 0.029). Similarly, more patients in calcified group had a history of hypertension compared to those in the noncalcified group (P 5 0.036).
Statin therapy at discharge and follow-up duration was comparable among the three groups.
| Changes in laboratory test
Serum levels of lipids and high-sensitivity C-reactive protein (hs-CRP)
at baseline and follow-up are shown in Table 2 . Low-density lipoprotein-cholesterol (LDL-C) significantly decreased from baseline to 6 months and 12 months in all three groups. Similarly, serum total cholesterol and triglycerides significantly decreased at 6 and 12 months compared with baseline in the three groups. Hs-CRP significantly decreased over time in both the spotty calcification group (P 5 0.002) and the noncalcified group (P 5 0.028). Serum levels of lipid and highsensitivity C-reactive protein were comparable between the groups at each time point between the three groups. The absolute changes of laboratory data from baseline to 12 month follow-up were similar between the three groups (Supporting Information Table 1, Figure 2 ).
| Angiographic findings
Lesion length was significantly shorter in the spotty calcification group compared to that in the calcified group at baseline (10.6 6 4.3 vs.
16.2 6 5.8 mm, P 5 0.001) and at the 6 month follow-up (11.4 6 4.4
vs. 16.4 6 5.6 mm, P 5 0.002). The diameter stenosis was greater in the calcified group than in the noncalcified group at baseline (P 5 0.029) and at the 6-month follow-up (P 5 0.026), while the minimum lumen diameter and the reference vessel diameter were similar among the three groups (Supporting Information Table 2 ).
| OCT findings
The changes in OCT findings are shown in Table 3 . FCT significantly increased from baseline to 6 and 12 months in all three groups under statin therapy. In detail, an increase of FCT was significantly sustained in the three groups, as shown in Figure 3 . The mean lipid arc decreased significantly from baseline to 12 months in the three groups. However, there was no significant difference in the absolute and percentage changes in FCT and the lipid arc at 6 and 12 months among the three groups. At baseline, the minimum lumen area (MLA), FCT, maximum lipid arc, and mean lipid arc were comparable Continuous variables are expressed as the mean 6 SD; categorical variables are expressed as number (percentage); P < .05 was considered significant. Abbreviations: 6M, 6 months; 12M, 12 months; BL, baseline; HDL-C, high-density lipoprotein cholesterol; Hs-crp, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation; TC, total cholesterol; TG, triglycerides. Intensive statin therapy induced a significant increase in FCT at 12 months compared to moderate statin therapy in the spotty calcification group (P 5 0.034).
The representative OCT images are shown in Figure 5 . There was a significant difference in the presence of cholesterol crystals in spotty calcification compared to noncalcified group at the 6 and 12 months follow-ups (P 5 0.042 and P 5 0.042, respectively) ( Table 5 ).
| D I SCUSSION
This is the first study to evaluate the response of nonculprit lipid-rich plaques containing spotty calcification under statin therapy. The major findings of the present study are as follows: First, FCT, as primary determinant of plaque vulnerability, increased continuously over time in the three groups irrespective of the presence of spotty calcification.
Furthermore, intensive statin therapy was more effective for increasing FCT in plaques containing spotty calcification. Second, patients with plaques containing spotty calcification were older and had a greater prevalence of hypertension.
In the present study, statin therapy was associated with a significant increase in FCT and smaller lipid arc at 12 months compared to baseline in the three groups. FCT is considered the most important determinant for plaque vulnerability and can be evaluated by OCT [13, 18] . Using OCT, a recent prospective, randomized study (EASY-FIT) demonstrated a greater increase of FCT and the stabilization of lipidrich plaques with higher dose of atorvastatin (20 vs. 5 mg/day) in a Japanese population. The effect of statin therapy on coronary plaques was also shown in a retrospective study, which reported the ability of statin therapy to increase FCT in nonculprit lesions of patients with acute coronary syndrome after 9 months [19, 20] . This effect was evident in our study: fibrous cap thickness in plaques with spotty calcification, calcification and noncalcified increased after 12 months of statin therapy. In our study, we evaluated nonculprit lipid-rich plaques, and statin therapy effectively increased FCT and reduced the lipid arc in the three groups. Spotty calcification has recently been introduced as a marker of high-risk plaque and plaque progression [21] . Conventionally, we may think that plaques containing spotty calcification might not respond to statin therapy. However, the spotty calcification group benefitted from statin therapy, and plaque stability was achieved in our study. Three different statin regimes of intensive (AT60) and moderate (AT 20 or RT 10) statin therapies were used in the present study in a Chinese population. Intensive statin therapy was more effective in Calcifications are reported to support plaque stability [22] . Both statin therapy dosage increased FCT in plaques containing calcification. These findings might contribute to important therapeutic target, which requires a statin to stabilize lesions and potentially lead to the understanding of OCT features in patients with ACS.
Previous studies described spotty calcifications as a feature of high-risk plaques [23, 24] . Using IVUS, Ehara et al. reported that the culprit lesions of patients with ACS were mostly specified by presence of spotty calcium associated with fibro-fatty plaques, while the culprit lesions were extensively calcified [6] . Fuji et al. discovered that ruptured plaques are associated with a larger number of calcium deposits within an arc of <90 degrees, a larger number of deep calcium deposits, and a remodeling index [25] . In the study, the term "spotty" refers to calcium deposits that are limited in size, whereas an IVUS study expanded the terms slightly by referring to small calcium deposits within the arc of <908; we employed this definition in the present study [6, 25] . Various studies have evaluated the relationship between different calcification patterns and plaque characteristics. However, no study has assessed the relationship between spotty calcification and plaque progression in nonculprit lipid-rich plaque after 12 months of statin therapy, using OCT, which is a high resolution imaging technique that could make our detection more accurate compared to previously used modalities.
Spotty calcification has been shown to be related to more unstable clinical presentation [6] . In our study, patients with spotty calcification at discharge used more nitrates, and it was assumed that patients had some clinical symptoms such as chest pain. Considering that there was a positive relationship between patients with acute myocardial infarction and spotty calcification in previous studies [25] , we think that the clinical symptoms were caused by other mechanisms since the statin therapy strategy was able to reduce the lipid core and increase FCT.
Detailing patients' clinical symptoms may be important for explaining the mechanical role of spotty calcification in clinical outcomes and is highly suggested for treatment. We admit that statin stabilizes the plaques containing spotty calcification; however, patients with spotty calcification may benefit from additional treatment. The risk factor of old age and history of hypertension observed in our patients in the spotty calcification group is in line with previous studies [7, 26] .
Spotty calcification has been demonstrated to be an active stage of atherosclerosis associated with inflammation [27] . Additionally, a positive feedback loop further stimulates macrophage activation, and prominent mineralization develops small calcification [3, 4] . Thus, as macrophage apoptosis results in the release of cellular components and lipids that form necrotic cores, rendering the plaques vulnerable to rupture [28, 29] , and macrophage-triggered calcification would possibly cause plaque vulnerability. In the present study, spotty calcification was associated with the presence of macrophage at baseline, although OCT may not be the best imaging modality for the verification of macrophage. The presence of macrophages changed over time between the three groups.
The present study had several limitations. First, this was a post hoc, sub-analysis of a randomized study, and the study population was small. Second, due to the practical difficulties of OCT pullback length, some nonculprit lesions located in the distal segments were missed.
Third, selection of the exact same site for FCT measurement was challenging at follow-up studies. However, all the identified markers were used to identify the same location. Fourth, according to OCT Continuous variables are expressed as the mean 6 SD; categorical variables are expressed as number (percentage); P < .05 was considered significant. Abbreviations: Cal, calcified; non-Cal, noncalcified; SD, standard deviation; Spotty, spotty calcification; TCFA, thin-cap fibroatheroma.
